MIRM

Mirum Pharmaceuticals Inc

98.08

Aug 25 • 3:59 PM ET +1.36 (1.41%)

98.08

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: BMRN KRYS MDGL RYTM AXSM INCY PTGX VKTX KROS NBIX

| Held by: VTI VB IWM XBI VBK VXF IWO IBB VTWO SCHA

Index	RUT
Market Cap	6.37B
Enterprise Value	6.69B
Income	-860.21M
Sales	618.07M
Book/sh	-0.16
Cash/sh	6.75
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	372
IPO	Jul 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	10.30
P/B	-
P/C	14.53
P/FCF	-
EV/EBITDA	-
EV/Sales	10.83
Quick Ratio	2.74
Current Ratio	2.86
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-14.55
EPS next Y	-0.76
EPS next Q	-0.53
EPS this Y	-3119.43%
EPS next Y	94.97%
EPS next 5Y	-
EPS past 3/5Y	51.26% 35.25%
Sales past 3/5Y	89.13% -
EPS Y/Y TTM	-1101.02%
Sales Y/Y TTM	44.02%
EPS Q/Q	-799.75%
Sales Q/Q	37.92%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-42.76% 5.93%

Insider Own	18.24%
Insider Trans	-1.82%
Inst Own	94.74%
Inst Trans	4.04%
ROA	-97.15%
ROE	-702.97%
ROIC	-114.68%
Gross Margin	81.65%
Oper. Margin	-14.76%
Profit Margin	-139.18%
SMA20	-2.99%
SMA50	-11.20%
SMA200	3.35%
Trades

Shs Outstand	64.75M
Shs Float	53.09M
Short Float	12.22%
Short Ratio	8.05
Short Interest	6.49M
52W High	130.00 -24.55%
52W Low	63.23 55.11%
Volatility	3.79% 4.24%
ATR (14)	4.40
RSI (14)	40.81
Beta	0.49
Rel Volume	0.58
Avg Volume	806.01K
Volume	471,934

Perf Week	-2.77%
Perf Month	-14.12%
Perf Quarter	-0.83%
Perf Half Y	-8.75%
Perf YTD	24.17%
Perf Year	36.58%
Perf 3Y	269.63%
Perf 5Y	546.54%
Perf 10Y	-
Recom	1.07
Target Price	138.21
Prev Close	96.72
Price	98.08
Change %	1.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-26	Initiated	Citigroup	Buy	$145
May-19-26	Initiated	Wolfe Research	Outperform	$145
Feb-18-26	Initiated	RBC Capital Mkts	Outperform	$130
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33

Show Previous Ratings

Aug-11-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-06-26 09:46AM	Citizens Says FDAs 'Unexpected' Phase 3 Request Clouds Mirums Near-Term Outlook MIRM Stock Crashes 15% (Stocktwits) -11.04%
Aug-05-26 10:02PM	Mirum Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary (Moby)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Jul-29-26 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 (Business Wire)
04:01PM	Loading…
Jul-13-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-14-26 04:35PM	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva (Business Wire)
Jun-11-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.89%
Jun-04-26 08:05AM	Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 (Business Wire)
May-30-26 12:00PM	Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-21-26 08:05AM	Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 (Business Wire)
May-14-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.26%
May-12-26 11:56PM	Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes (Business Wire)
04:01PM	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering (Business Wire)
08:00AM	Loading…
08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-06-26 08:29PM	Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby) -6.50%
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-05-26 08:59AM	Idexx Claws Down A Beat As Shares Bound Higher On A Guidance Hike (Investor's Business Daily)
May-04-26 12:59PM	Why This Biotech ETF - The IBD Stock Of The Day - Just Reentered Its Buy Zone (Investor's Business Daily) +9.59%
12:05PM	The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A Record (Investor's Business Daily)
08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis (Business Wire)
May-03-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 (Business Wire)
Apr-29-26 04:01PM	Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (Business Wire)
Apr-27-26 08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus (Business Wire)
Mar-16-26 08:00AM	Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Additional Rare Cholestatic Liver Diseases (Business Wire)
Mar-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-26 08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
Mar-05-26 08:00AM	Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus (Business Wire) -5.59%
Feb-26-26 10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks) -15.13%
12:04AM	Loading…
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-25-26 08:00PM	Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:25PM	Mirum Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update (Business Wire)
Feb-23-26 07:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-19-26 06:03AM	ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (Zacks)
Feb-18-26 04:01PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

CEO & DirectorMr. Christopher Peetz

Ph.D.Mr. Peter Radovich M.B.A.

M.S.Mr. Eric H. Bjerkholt M.B.A.

Chief Medical OfficerDr. Joanne M. J. Quan M.D.

Chief Technical OfficerDr. Jean-Luc Girardet Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 18 '26	Option Exercise	6.27	40,000	250,800	41,274	Aug 19 06:19 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 18 '26	Sale	100.00	40,000	4,000,000	1,274	Aug 19 06:19 PM
JOLANDA MARIE HOWE	Officer	Aug 18 '26	Proposed Sale	100.00	40,000	4,000,000		Aug 18 05:24 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 11 '26	Sale	99.90	6,001	599,510	36,355	Aug 12 05:14 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 10 '26	Option Exercise	2.94	20,000	58,720	214,309	Aug 11 05:41 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 10 '26	Sale	98.92	20,000	1,978,402	194,309	Aug 11 05:41 PM
ERIC BJERKHOLT	Officer	Aug 11 '26	Proposed Sale	99.90	6,001	599,510		Aug 11 04:11 PM
CHRISTOPHER PEETZ	Officer	Aug 10 '26	Proposed Sale	98.92	20,000	1,978,346		Aug 10 04:17 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 03 '26	Sale	105.29	1,840	193,734	1,274	Aug 05 04:26 PM
JOLANDA MARIE HOWE	Officer	Aug 03 '26	Proposed Sale	105.29	1,840	193,734		Aug 03 04:07 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 06 '26	Option Exercise	2.94	20,000	58,720	214,309	Jul 08 05:12 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 06 '26	Sale	122.27	20,000	2,445,382	194,309	Jul 08 05:12 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jul 06 '26	Sale	122.25	5,000	611,273	42,181	Jul 08 05:07 PM
CHRISTOPHER PEETZ	Officer	Jul 06 '26	Proposed Sale	122.27	20,000	2,445,434		Jul 06 04:10 PM
ERIC BJERKHOLT	Officer	Jul 06 '26	Proposed Sale	122.25	5,000	611,270		Jul 06 04:09 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 01 '26	Sale	120.00	2,721	326,520	3,114	Jul 02 06:01 PM
JOLANDA MARIE HOWE	Officer	Jul 01 '26	Proposed Sale	120.00	2,721	326,520		Jul 01 05:24 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jun 17 '26	Sale	101.95	2,594	264,458	5,835	Jun 18 06:39 PM
JOLANDA MARIE HOWE	Officer	Jun 17 '26	Proposed Sale	101.95	2,594	264,458		Jun 17 04:01 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 09 '26	Option Exercise	26.49	2,393	63,391	47,181	Jun 09 09:21 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 08 '26	Sale	93.82	5,000	469,077	44,788	Jun 09 09:21 PM
Radovich Peter	PRESIDENT AND COO	Jun 05 '26	Option Exercise	19.19	16,988	326,000	57,260	Jun 08 04:27 PM
ERIC BJERKHOLT	Officer	Jun 08 '26	Proposed Sale	93.81	5,000	469,073		Jun 08 04:20 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Option Exercise	2.94	30,000	88,080	224,309	Jun 02 07:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Sale	95.84	30,000	2,875,103	194,309	Jun 02 07:50 PM
Ramasastry Saira	Director	Jun 01 '26	Sale	100.00	3,977	397,700	0	Jun 02 07:50 PM
CHRISTOPHER PEETZ	Officer	Jun 01 '26	Proposed Sale	95.84	30,000	2,875,107		Jun 01 05:33 PM
SAIRA RAMASASTRY	Director	Jun 01 '26	Proposed Sale	100.00	3,977	397,700		Jun 01 04:04 PM
Ramasastry Saira	Director	May 15 '26	Option Exercise	23.51	2,000	47,020	2,000	May 18 08:32 PM
Ramasastry Saira	Director	May 15 '26	Sale	109.47	2,000	218,940	0	May 18 08:32 PM
SAIRA RAMASASTRY	Director	May 15 '26	Proposed Sale	109.47	2,000	218,940		May 15 04:07 PM
Ramasastry Saira	Director	Apr 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Apr 16 08:40 PM
Ramasastry Saira	Director	Apr 15 '26	Sale	96.90	2,000	193,800	0	Apr 16 08:40 PM
SAIRA RAMASASTRY	Director	Apr 15 '26	Proposed Sale	96.90	2,000	193,800		Apr 15 04:11 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	49,788	Mar 17 07:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	18,864	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Option Exercise	23.51	2,000	47,020	2,000	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Sale	90.76	2,000	181,520	0	Mar 17 07:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 16 '26	Sale	91.98	16,515	1,519,015	40,272	Mar 17 07:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 16 '26	Sale	91.98	4,732	435,239	8,429	Mar 17 07:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 16 '26	Sale	91.98	40,985	3,769,714	194,309	Mar 17 07:30 PM
ERIC BJERKHOLT	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:03 PM
Joanne Quan	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:00 PM
Peter Radovich	Officer	Mar 16 '26	Proposed Sale	92.64	16,515	1,529,950		Mar 17 06:58 PM
Jolanda Howe	Officer	Mar 16 '26	Proposed Sale	92.64	4,732	438,372		Mar 17 06:55 PM
Christopher Peetz	Officer	Mar 16 '26	Proposed Sale	92.64	40,985	3,796,850		Mar 17 06:50 PM
SAIRA RAMASASTRY	Director	Mar 16 '26	Proposed Sale	90.76	2,000	181,520		Mar 16 04:04 PM
Radovich Peter	PRESIDENT AND COO	Mar 06 '26	Option Exercise	15.87	5,912	93,823	26,567	Mar 11 04:05 PM
Ramasastry Saira	Director	Feb 13 '26	Option Exercise	23.51	2,000	47,020	2,000	Feb 17 04:38 PM
Ramasastry Saira	Director	Feb 13 '26	Sale	102.09	2,000	204,180	0	Feb 17 04:38 PM
SAIRA RAMASASTRY	Director	Feb 13 '26	Proposed Sale	102.09	2,000	204,180		Feb 13 04:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM

Open in Screener

ACAD

Acadia Pharmaceuticals Inc

30.57

Aug 25 • 3:59 PM ET +0.92 (3.10%)

30.75

Aftermarket • 7:55 PM ET +0.18 (0.59%)

Healthcare Biotechnology USA Mid NASD

ACAD Acadia Pharmaceuticals Inc daily Stock Chart

Peers: AXSM XENE NBIX BMRN VKTX INCY MDGL ALKS KROS BIIB

| Held by: IJR XBI VTI IWM VB VBK VXF IBB IWO IJT

Index	RUT
Market Cap	5.27B
Enterprise Value	4.38B
Income	380.48M
Sales	1.14B
Book/sh	7.59
Cash/sh	5.55
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	798
IPO	May 27, 2004

P/E	13.77
Forward P/E	33.63
PEG	-
P/S	4.63
P/B	4.03
P/C	5.51
P/FCF	36.17
EV/EBITDA	44.57
EV/Sales	3.85
Quick Ratio	3.30
Current Ratio	3.39
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	2.22
EPS next Y	0.91
EPS next Q	0.20
EPS this Y	-73.34%
EPS next Y	48.25%
EPS next 5Y	-12.33%
EPS past 3/5Y	- -
Sales past 3/5Y	27.48% 19.39%
EPS Y/Y TTM	68.42%
Sales Y/Y TTM	11.75%
EPS Q/Q	15.24%
Sales Q/Q	16.40%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	163.93% 3.85%

Insider Own	1.32%
Insider Trans	-3.35%
Inst Own	97.73%
Inst Trans	-0.29%
ROA	25.64%
ROE	35.74%
ROIC	27.85%
Gross Margin	91.13%
Oper. Margin	7.59%
Profit Margin	33.42%
SMA20	7.07%
SMA50	16.64%
SMA200	26.11%
Trades

Shs Outstand	172.13M
Shs Float	170.03M
Short Float	5.57%
Short Ratio	5.88
Short Interest	9.48M
52W High	30.96 -1.26%
52W Low	19.69 55.26%
Volatility	2.93% 3.36%
ATR (14)	0.95
RSI (14)	67.86
Beta	0.86
Rel Volume	0.94
Avg Volume	1.61M
Volume	1,522,957

Perf Week	1.29%
Perf Month	20.40%
Perf Quarter	43.79%
Perf Half Y	24.32%
Perf YTD	14.45%
Perf Year	20.73%
Perf 3Y	6.89%
Perf 5Y	77.94%
Perf 10Y	-5.36%
Recom	1.62
Target Price	34.00
Prev Close	29.65
Price	30.57
Change %	3.10%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-26	Upgrade	BofA Securities	Neutral → Buy	$29
Feb-24-26	Initiated	Wolfe Research	Outperform	$33
Feb-23-26	Upgrade	Mizuho	Neutral → Outperform	$35
Oct-21-25	Initiated	Citigroup	Buy	$33
May-21-25	Upgrade	Deutsche Bank	Hold → Buy	$35
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33

Show Previous Ratings

Aug-24-26 03:01AM	European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union (Business Wire)
Aug-10-26 04:36PM	Immunic appoints Elena Ridloff to board of directors (Proactive)
Aug-05-26 01:06AM	ACADIA Pharmaceuticals Inc (ACAD) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +6.08%
Aug-04-26 04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results (Business Wire) +6.01%
Jul-30-26 05:57PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
09:05AM	Loading…
Jul-20-26 09:05AM	Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis (Business Wire)
Jul-15-26 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 (Business Wire)
Jul-06-26 09:04AM	Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer (Business Wire)
Jun-26-26 12:30PM	ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe (Stocktwits) +6.75%
06:49AM	DAYBU (trofinetide) Recommended for Approval in the European Union by CHMP (Business Wire)
05:24AM	On second try, Acadia drug gets nod from European regulators (BioPharma Dive)
Jun-12-26 05:31AM	Rapport fully prepared to launch seizure drug solo, CEO says (BioPharma Dive)
May-08-26 09:15AM	Earnings To Watch: AcadeMedia AB (OSTO:ACAD) Reports Q3 2026 Result (GuruFocus.com)
May-06-26 04:21PM	Acadia: Q1 Earnings Snapshot (Associated Press) +5.03%
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance (Business Wire)
04:05PM	Loading…
Apr-30-26 04:05PM	Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career (Business Wire)
Apr-28-26 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Apr-17-26 09:05AM	Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-15-26 04:05PM	Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 (Business Wire)
Apr-07-26 09:05AM	Acadia Pharmaceuticals Announces DAYBUE STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome (Business Wire)
Mar-25-26 02:51PM	Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback (Proactive) +5.01%
09:48AM	Arm upgraded, Mondelez downgraded: Wall Street's top analyst calls (The Fly)
Mar-12-26 04:05PM	Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum (Business Wire)
Mar-09-26 11:40AM	JAZZ or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Mar-05-26 05:07AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) (Zacks)
Mar-04-26 08:03AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Zacks)
Mar-03-26 04:05PM	Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors (Business Wire)
Mar-02-26 05:32PM	ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 (MarketBeat) -7.13%
04:05PM	Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome (Business Wire)
01:45PM	Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains (Insider Monkey)
09:52AM	Loading…
Feb-26-26 09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
08:30AM	ACADIA Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby)
12:05AM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-25-26 07:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates (Zacks)
06:32PM	ACADIA Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:37PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview (Business Wire)
Feb-23-26 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Feb-20-26 10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-18-26 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:36AM	Ovintiv to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
12:50AM	Oppenheimer Maintains A Balanced Outlook on ACADIA Pharmaceuticals Inc. (ACAD) For 2026 (Insider Monkey)
Feb-04-26 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (Business Wire)
Feb-03-26 12:44PM	EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug (Benzinga) -5.24%
10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
Feb-02-26 04:05PM	Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union (Business Wire)
12:10PM	Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-28-26 11:40AM	FTRE or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-13-26 02:06PM	ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf (MarketBeat)
09:00AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-12-26 04:01PM	Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience (Bloomberg)
11:40AM	FTRE vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Dec-22-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Dec-18-25 04:05PM	Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 (Business Wire)
Dec-12-25 08:00AM	Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily)
Dec-10-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-05-25 11:30AM	Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? (Zacks)
Dec-03-25 09:17AM	Acadia to pivot to Alzheimers psychosis pipeline, accd to Wall Street analysts (Investing.com)
Nov-28-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-20-25 04:05PM	Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (Business Wire)
Nov-12-25 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
12:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
04:18PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview (Business Wire)
12:04PM	Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y (Zacks)
Oct-29-25 10:00AM	Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
12:00PM	Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:55AM	Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-22-25 03:41PM	Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-15-25 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) +6.78% -5.15%
Oct-09-25 11:40AM	QGEN vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Oct-02-25 09:04AM	Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders (Business Wire)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) -9.92%
09:32AM	Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges (Investor's Business Daily)
09:27AM	Lithium Americas, Oracle, Acadia Pharma: Trending Tickers (Yahoo Finance Video)
07:28AM	Acadia to scrap Prader-Willi drug after study setback (BioPharma Dive)
07:00AM	Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint (Business Wire)
02:12AM	ACADIA Pharmaceuticals (ACAD) Announces Interim Results From LOTUS study on DAYBUE (Insider Monkey)
Sep-12-25 04:05PM	Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology (Business Wire)
Sep-11-25 11:13AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome (Insider Monkey)
Sep-08-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
04:53AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial (Insider Monkey)
Aug-26-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-25-25 04:05PM	Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer (Business Wire)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

CEO & DirectorMs. Catherine E. Owen Adams

Executive VP & CFOMr. Mark C. Schneyer

Executive VPMs. Jennifer J. Rhodes J.D.

Executive VP and Head of Research & DevelopmentDr. Elizabeth H. Z. Thompson Ph.D.

Executive VP & Chief Commercial OfficerMr. Thomas Andrew Garner

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 06 '26	Option Exercise	17.84	14,292	254,969	82,120	Aug 07 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 05 '26	Option Exercise	17.84	5,849	104,346	73,677	Aug 07 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 06 '26	Sale	29.22	14,292	417,604	67,828	Aug 07 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 05 '26	Sale	29.00	5,849	169,638	67,828	Aug 07 06:00 PM
Schneyer Mark C.	Officer	Aug 05 '26	Proposed Sale	27.15	5,849	158,800		Aug 05 04:49 PM
Thompson Elizabeth H.Z.	EVP, Head of Research & Dev	Jul 30 '26	Sale	26.13	16,558	432,663	18,994	Jul 31 06:00 PM
Kihara James	Officer	Jun 26 '26	Proposed Sale	26.00	11,421	297,000		Jun 26 03:09 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 26 '26	Sale	21.18	5,401	114,393	24,509	May 27 06:00 PM
JAMES K KIHARA	Officer	May 26 '26	Proposed Sale	21.18	5,401	114,394		May 26 04:02 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 04 '26	Sale	21.79	1,332	29,024	29,129	May 05 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 04 '26	Sale	21.79	3,506	76,396	66,145	May 05 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 07 '26	Sale	22.20	2,709	60,140	62,836	Apr 07 07:57 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 07 '26	Sale	22.20	1,030	22,866	27,865	Apr 07 07:55 PM
Owen Adams Catherine	Chief Executive Officer	Mar 24 '26	Option Exercise	0.00	23,509	0	26,444	Mar 26 08:00 PM
Owen Adams Catherine	Chief Executive Officer	Mar 25 '26	Sale	21.47	11,641	249,932	14,803	Mar 26 08:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Mar 24 '26	Option Exercise	0.00	7,515	0	15,124	Mar 26 08:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Mar 25 '26	Sale	21.47	3,844	82,531	11,280	Mar 26 08:00 PM
Thompson Elizabeth H.Z.	EVP, Head of Research & Dev	Mar 25 '26	Sale	21.47	3,435	73,749	3,280	Mar 26 08:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 26 '26	Sale	21.65	1,109	24,011	26,885	Mar 26 08:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 25 '26	Sale	21.47	833	17,885	25,852	Mar 26 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 25 '26	Sale	21.47	4,177	89,680	57,299	Mar 26 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '26	Sale	21.65	3,208	69,456	60,269	Mar 26 08:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 06 '26	Option Exercise	0.00	12,944	0	14,559	Feb 10 06:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 09 '26	Sale	23.38	6,950	162,491	7,609	Feb 10 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 18 '25	Sale	23.69	10,262	243,114	53,338	Nov 19 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 18 '25	Sale	23.69	4,084	96,754	25,058	Nov 19 06:00 PM
Daly James M	Director	Nov 10 '25	Sale	22.37	30,000	670,983	4,041	Nov 12 06:00 PM
James M Daly	Director	Nov 10 '25	Proposed Sale	22.37	30,000	670,983		Nov 10 05:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Sep 15 '25	Sale	23.65	3,498	82,728	43,447	Sep 16 06:00 PM
GAROFALO ELIZABETH A.	Director	Sep 02 '25	Sale	25.98	1,600	41,560	25,382	Sep 03 06:00 PM

MIRM

Mirum Pharmaceuticals Inc

ACAD

Acadia Pharmaceuticals Inc

Upgrade your Finviz experience